PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Posterübersicht
P 26 Gonokokkenresistenz in Österreich - Update 2011
Angelika Stary, Claudia Heller-Vitouch, Natalie Hartl, Gudrun Heidler, Eva-Maria
Vinzelj-Horvath, Alexandra Geusau, Klemens Rappersberger, Peter Komericki,
Josef Auböck, Matthias Schmuth, Maria Haller (Wien, Graz, Linz, Innsbruck)
P 27 Identification of HPV vaccine-genotypes in a female STI population group
Natalie Isabella Hartl, Claudia Heller-Vitouch, Angelika Stary (Wien)
P 28 Eine niedrige CD4 Zellzahl zum Zeitpunkt der HIV Diagnose ist auch
für Nicht-AIDS definierende Todesursachen mit einer erhöhten
Mortalitätsrate assoziiert.
G. Sturm, M. Sarcletti, A. Rieger, M. Geit, S. Gogl, R. Zangerle (Innsbruck, Wien, Linz)
P 29 The Therapeutic History of a Recalcitrant Case of Psoriasis Vulgaris
Jenny Deluca, Elena Polestra, Nadia Bonometti, Dunja Vigl, Tobias Thuile,
Klaus Eisendle (Bolzano)
P 30 Intermediate to long-term efficacy and safety of etanercept: report from
the psoriasis registry Austria
Martin Inzinger, Isabel Roschatt, Wolfgang Weger, Wolfgang Salmhofer,
Franz Quehenberger, Peter Wolf (Graz)
P 31 Generalisierte Erythrodermie unter Adalimumab - ein Fallbericht
Karin Dunst-Huemer, Christine Scheurecker, Julia Danzmair, Josef Auböck (Linz)
P 32 Long-term safety of ustekinumab in patients with moderate to severe
psoriasis through up to 5 years of continuous follow-up
K. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan,
M.C. Hsu, V. Ho, P.D. Ghislain, B. Strober, K. Reich (Waterloo, Manchester, Chicago,
New York, Spring House, Vancouver, Brüssel, Farmington, Hamburg)
P 33 Long-term treatment with ustekinumab does not compromise the
immune response to T-cell dependent or T-cell independent vaccines in
patients with moderate to severe psoriasis: A comparison of ustekinumab-treated
versus untreated psoriasis patients
C. Brodmerkel, R. Langley, K. Papp, M. Bourcier, Y. Poulin, V. Ho, L. Guenther,
M.C. Hsu, P.O. Szapary (Spring House, Halifax, Waterloo, Moncton, Quebec,
Vancouver, London)
P 34 Long-term safety and efficacy of ustekinumab in patients with psoriasis
inadequately responding to methotrexate: Week 52 TRANSIT results
C. Paul, L. Puig, T. Luger, J. Lambert, S. Chimenti, G. Girolomoni, J.-F. Nicolas,
K. Kragballe, E. Rizova, S. Mistry, P. Bergmans, J. Barker, K. Reich (Toulouse,
Barcelona, Munster, Ghent, Rome, Verona, Lyon, Arhus, Issy Les Moulineaux,
High Wycombe, Tilburg, London, Hamburg)
36